Twin SUBLIVAC® Grasses Clinical Efficacy Study

Inclusion Criteria: * Subjects with allergic rhinoconjunctivitis with or without mild asthma FEV1 ≥ 70%) for at least 2 years. Their allergic symptoms should be related to grass pollen Use of anti-allergy symptomatic medication in the last pollen season (or, in case of a low pollen season, in one of the two previous years) * A positive skin prick test (\>3 mm) for early flowering treesgrasses and specific serum IgE-test(\>1 U/ml) for grass pollen (Lolium perenne, Phleum pratense and Poa pratensis). Exclusion Criteria: * A positive SPT for perennial allergens of house dust mite * Allergy to any of the excipients * Symptoms related to concomitant sensitisation to perennial allergens of pets * Chronic asthma or emphysema, particularly with a FEV1 \< 70 % of predicted value or use of inhalation corticosteroids outside grass and tree pollen season for more than two episodes and/or longer than fourteen days * Use of symptomatic medication for more than three episodes and/or longer than three days outside the tree- or grass pollen season * Serious immuno-pathological diseases or malignancies (including auto-immune diseases, tuberculosis, HIV) * Inflammation and infection of the target organ * Severe atopic dermatitis requiring systemic immuno-suppressive medication * Allergen specific immuno-therapy treatment within the last 5 years for a period longer than three months * History of life threatening anaphylactic events, including anaphylactic food allergy, insect venom anaphylaxis, exercise or drug induced anaphylaxis * A positive pregnancy test, lactation or inadequate contraceptive measures Alcohol- or drug abuse * Lack of co-operation or severe psychological disorders